tiprankstipranks
Trending News
More News >
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) AI Stock Analysis

Compare
562 Followers

Top Page

PH

Phio Pharmaceuticals

(NASDAQ:PHIO)

Rating:42Neutral
Price Target:
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
Positive Factors
Clinical Trials
PH-762 has demonstrated impressive clinical activity and exhibited favorable safety in an early-stage Phase 1b trial.
Market Positioning
The stock is considered undervalued with significant potential upside, driven by PH-762's promising trial results and the company's strategic positioning.
Safety Profile
The safety monitoring committee recommends PH-762 to advance to final cohorts, indicating a clean safety profile.
Negative Factors
Funding Challenges
Factors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.
Market Competition
Although the skin cancer therapy market is becoming increasingly crowded, a high unmet need persists due to the tumor's high incidence and less than optimal efficacy of available treatment options.

Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)

Phio Pharmaceuticals Business Overview & Revenue Model

Company DescriptionPhio Pharmaceuticals Corp. is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company specializes in the field of RNA interference (RNAi) and is pioneering the development of self-delivering RNAi (sd-rxRNA) therapeutics aimed at enhancing the efficacy of existing cancer treatments by targeting various pathways involved in tumor growth and immune evasion.
How the Company Makes MoneyPhio Pharmaceuticals generates revenue through strategic partnerships, research collaborations, and licensing agreements related to its RNAi technology platform. The company aims to out-license its proprietary sd-rxRNA technology to larger pharmaceutical or biotechnology companies, which can incorporate these therapies into their own cancer treatment pipelines. Additionally, Phio may receive milestone payments and royalties from these partnerships based on the successful development and commercialization of its therapeutics. The company might also secure funding through grants and government programs aimed at supporting innovative cancer research.

Phio Pharmaceuticals Financial Statement Overview

Summary
Phio Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing operational losses. The balance sheet shows low leverage, but the cash flow situation is concerning due to consistent cash burn and a reliance on external financing. The company must focus on revenue generation and efficient cash management to improve its financial health.
Income Statement
10
Very Negative
Phio Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of product commercialization. The net income remains negative, reflecting persistent losses. The company's inability to generate revenue and its ongoing operational losses are significant concerns.
Balance Sheet
40
Negative
The company maintains a strong equity position relative to its assets, with a high equity ratio indicating minimal leverage. However, the substantial cash burn and diminishing cash reserves are potential risks if new funding is not secured.
Cash Flow
30
Negative
Operating cash flow remains negative, indicative of ongoing operational challenges. While the company has managed to secure financing to cover cash flow needs, the absence of free cash flow growth poses a risk to long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-1.00K0.00-6.33M-193.00K-192.00K-183.00K
EBITDA-5.11M-7.12M-10.64M-11.29M-13.09M-8.72M
Net Income-6.76M-7.15M-10.83M-11.30M-13.21M-8.79M
Balance Sheet
Total Assets9.36M5.74M9.36M12.81M25.17M15.74M
Cash, Cash Equivalents and Short-Term Investments8.49M5.38M8.49M11.78M24.06M14.24M
Total Debt35.00K0.0035.00K305.00K295.00K642.00K
Total Liabilities1.63M1.01M1.63M1.98M3.24M2.72M
Stockholders Equity7.73M4.72M7.73M10.84M21.93M13.02M
Cash Flow
Free Cash Flow-5.79M-7.11M-10.75M-12.25M-11.91M-8.82M
Operating Cash Flow-5.78M-7.11M-10.75M-12.13M-11.86M-8.80M
Investing Cash Flow6.00K8.00K-5.00K-121.00K-51.00K-19.00K
Financing Cash Flow13.17M4.00M7.41M-26.00K21.72M16.13M

Phio Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.55
Price Trends
50DMA
2.12
Positive
100DMA
1.85
Positive
200DMA
2.28
Positive
Market Momentum
MACD
0.08
Negative
RSI
59.52
Neutral
STOCH
82.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Positive. The current price of 2.55 is above the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.12, and above the 200-day MA of 2.28, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.52 is Neutral, neither overbought nor oversold. The STOCH value of 82.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHIO.

Phio Pharmaceuticals Risk Analysis

Phio Pharmaceuticals disclosed 26 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Phio Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.30-61.93%2.28%16.62%1.04%
42
Neutral
$12.24M-76.12%81.71%
40
Underperform
$3.12M-215.66%-21.03%47.41%
40
Underperform
$3.12M-215.66%-21.03%47.41%
34
Underperform
$8.80M-538.87%-26.02%
24
Underperform
$9.47M<0.0113.29%-261.69%
15
Underperform
$4.43M-206.26%75.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PHIO
Phio Pharmaceuticals
2.55
-3.01
-54.14%
OTRK
Ontrak
0.44
-2.96
-87.06%
OTRK
Ontrak
0.44
-2.96
-87.06%
GTBP
GT Biopharma
2.17
-0.67
-23.59%
AEON
AEON Biopharma
0.79
-78.41
-99.00%
DRMA
Dermata Therapeutics
0.70
-1.73
-71.19%

Phio Pharmaceuticals Corporate Events

Executive/Board Changes
Phio Pharmaceuticals Appoints David Deming to Board
Positive
Feb 20, 2025

Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025